Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Liquidia Corporation Liquidia Corporation to Report Third Quarter 2024 Financial Results on November 11, 2024 November 04, 2024 From Liquidia Corporation Via GlobeNewswire Tickers LQDA United States Supreme Court Declines to Review Rulings that Invalidate United Therapeutics’ Patent October 07, 2024 From Liquidia Corporation Via GlobeNewswire Tickers LQDA Liquidia and Pharmosa Biopharm Expand Collaboration to Develop Sustained Release Inhaled Treprostinil (L606) October 02, 2024 From Liquidia Corporation Via GlobeNewswire Tickers LQDA Liquidia Announces Poster Presentation and Medical Theater at the CHEST 2024 Annual Meeting September 30, 2024 From Liquidia Corporation Via GlobeNewswire Tickers LQDA Court Finds United Therapeutics’ Interference with Launch of Generic Treprostinil Injection Caused Losses of More Than $137 Million September 16, 2024 From Liquidia Corporation Via GlobeNewswire Tickers LQDA Liquidia Corporation Announces Raise of $67.5 Million from New Common Stock Financings and $32.5 Million Advance from HealthCare Royalty Under Current Financing Agreement September 11, 2024 From Liquidia Corporation Via GlobeNewswire Tickers LQDA Liquidia to Present at Upcoming Investor Conferences August 28, 2024 From Liquidia Corporation Via GlobeNewswire Tickers LQDA Liquidia Files Litigation to Challenge Regulatory Exclusivity Blocking Access to YUTREPIA™ (treprostinil) inhalation powder for Patients Suffering with PAH and PH-ILD August 22, 2024 From Liquidia Corporation Via GlobeNewswire Tickers LQDA U.S. FDA Grants Tentative Approval of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) August 19, 2024 From Liquidia Corporation Via GlobeNewswire Tickers LQDA Liquidia Announces Poster Presentations at the PHA 2024 International PH Conference and Scientific Sessions August 16, 2024 From Liquidia Corporation Via GlobeNewswire Tickers LQDA Liquidia Corporation Reports Second Quarter 2024 Financial Results and Provides Corporate Update August 07, 2024 From Liquidia Corporation Via GlobeNewswire Tickers LQDA Liquidia Corporation to Report Second Quarter 2024 Financial Results on August 7, 2024 July 31, 2024 From Liquidia Corporation Via GlobeNewswire Tickers LQDA Liquidia Announces Poster Presentations at the 7th World Symposia on Pulmonary Hypertension (WSPH) June 18, 2024 From Liquidia Corporation Via GlobeNewswire Tickers LQDA District Court Issues Favorable Ruling and Denies United Therapeutics’ Request to Block YUTREPIA™ Launch June 03, 2024 From Liquidia Corporation Via GlobeNewswire Tickers LQDA Liquidia Corporation Reports First Quarter 2024 Financial Results and Provides Corporate Update May 13, 2024 From Liquidia Corporation Via GlobeNewswire Tickers LQDA Liquidia Corporation to Present at the 2024 Jefferies Global Healthcare Conference May 29, 2024 From Liquidia Corporation Via GlobeNewswire Tickers LQDA Liquidia Announces Poster Presentation at the American Thoracic Society (ATS) 2024 International Conference on Its Open-Label Safety Study of L606 (Liposomal Treprostinil) in Patients with PAH and PH-ILD May 10, 2024 From Liquidia Corporation Via GlobeNewswire Tickers LQDA Liquidia Corporation to Present at BofA Securities Health Care Conference 2024 May 07, 2024 From Liquidia Corporation Via GlobeNewswire Tickers LQDA Liquidia Corporation to Report First Quarter 2024 Financial Results on May 14, 2024 May 07, 2024 From Liquidia Corporation Via GlobeNewswire Tickers LQDA Liquidia Corporation to Present at 23rd Annual Needham Virtual Healthcare Conference April 02, 2024 From Liquidia Corporation Via GlobeNewswire Tickers LQDA Update on Favorable Legal and Regulatory Outcomes Clearing Path for Potential FDA approval of YUTREPIA™ (treprostinil) inhalation powder April 01, 2024 From Liquidia Corporation Via GlobeNewswire Tickers LQDA Liquidia Corporation Reports Full Year 2023 Financial Results and Provides Corporate Update March 13, 2024 From Liquidia Corporation Via GlobeNewswire Tickers LQDA Liquidia Corporation to Report Full Year 2023 Financial Results on Wednesday, March 13, 2024 March 06, 2024 From Liquidia Corporation Via GlobeNewswire Tickers LQDA Liquidia Corporation Announces Poster Presentation at the Pulmonary Vascular Research Institute 2024 Annual Congress January 30, 2024 From Liquidia Corporation Via GlobeNewswire Tickers LQDA Liquidia Corporation Provides Update on New Drug Application for YUTREPIA™ (treprostinil) inhalation powder January 25, 2024 From Liquidia Corporation Via GlobeNewswire Tickers LQDA Liquidia Corporation Announces Updates to Operations Leadership January 19, 2024 From Liquidia Corporation Via GlobeNewswire Tickers LQDA Liquidia Corporation Files Response to United Therapeutics Lawsuit and Files Counterclaims January 08, 2024 From Liquidia Corporation Via GlobeNewswire Tickers LQDA Liquidia Provides Update on Clinical Pipeline Targeting PAH and PH-ILD January 05, 2024 From Liquidia Corporation Via GlobeNewswire Tickers LQDA Liquidia Corporation Announces $100 Million in New Financings January 04, 2024 From Liquidia Corporation Via GlobeNewswire Tickers LQDA Liquidia Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference January 02, 2024 From Liquidia Corporation Via GlobeNewswire Tickers LQDA Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
